ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

08 5 2024 17:47:25 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

04 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

26 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

21 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

19 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

12 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

08 3 2024 08:50:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

01 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 1 2024 16:15:20 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

13 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

13 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

07 11 2023 16:01:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

06 11 2023 16:01:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

06 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

02 11 2023 16:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

27 10 2023 09:25:00 提供 Nasdaq GlobeNewswire